Dr. Michel J. Tremblay is a regular researcher in the field of infectious and immune diseases at the CHU Research Center of Québec-Laval University. He is also a Professor in the Department of Microbiology-Infectiology and Immunology of the School of Medicine at Laval University, and holds the Canada Research Chair in Human Immuno-Retrovirology.
He has been Vice-Dean, Research and Graduate Studies at the Faculty of Medicine, and is currently Assistant Vice-President, Research, Creation and Innovation at Laval University. Dr. Tremblay has published over 200 articles in peer-reviewed scientific journals, and to date has received nearly $ 15 million in funding as a principal investigator and just under $ 40 million in funding as co-researcher for his research projects. Dr. Tremblay has received several awards and distinctions, including the André Dupont Award from the Clinical Research Club of Quebec and the Léo-Pariseau Award from ACFAS. Dr. Tremblay is a member of the Canadian Research Consortium on HIV Healing (CanCURE) which is funded by the Canadian Institutes of Health Research (CIHR).
His research aims to deepen our knowledge of the pathogenesis of human immunodeficiency virus (HIV) infection, the etiologic agent of Acquired Immunodeficiency Syndrome (AIDS). His research focuses on several facets of HIV infection, such as the complex interactions that occur between HIV and certain target cells of the virus (e.g., macrophages, CD4 T cells, astrocytes, etc.) and large-scale analysis of gene expression patterns following viral infection, using DNA microarrays and RNA sequencing in combination with powerful bioinformatic tools.
2705, boulevard Laurier
RC-709
Québec, Québec
Canada G1V 4G2
- Barat, CorinneEmployeeCHUL+1 418-525-4444, extension 47959+1 418-654-2715corinne.barat@crchudequebec.ulaval.ca
2705, boulevard Laurier
R2701.2
Québec, Québec
Canada G1V 4G2 - Breton, YannDoctoral studentCHUL+1 418-525-4444, extension 49318+1 418-654-2715yann.breton.1@ulaval.caYann.Breton@crchudequebec.ulaval.ca
2705, boulevard Laurier
R-2701
Québec, Québec
Canada G1V 4G2 - Côté, CarolineEmployeeCHUL+1 418-525-4444, extension 48624+1 418-654-2715caroline.cote@crchudequebec.ulaval.ca
2705, boulevard Laurier
RC-709
Québec, Québec
Canada G1V 4G2 - Hany, LaurentDoctoral studentCHUL+1 418-525-4444, extension 49318laurent.hany.1@ulaval.caLaurent.Hany@crchudequebec.ulaval.ca
2705, boulevard Laurier
RC-709
Québec, Québec
Canada G1V 4G2 - Sénécal, VincentDoctoral studentCHUL+1 418-525-4444, extension 47089vincent.senecal.1@ulaval.caVincent.Senecal2@crchudequebec.ulaval.ca
2705, boulevard Laurier
RC-709
Québec, Québec
Canada G1V 4G2
HIV-1 infection and latency-reversing agents bryostatin-1 and JQ1 disrupt amyloid beta homeostasis in human astrocytes.
Journal ArticleGlia, 68 (11), pp. 2212-2227, 2020, ISSN: 0894-1491.
Abstract | Links: 
Medroxyprogesterone acetate alters the vaginal microbiota and microenvironment in women and increases susceptibility to HIV-1 in humanized mice.
Journal ArticleDis Model Mech, 12 (10), 2019, ISSN: 1754-8403.
Abstract | Links:
Expression of MDM2 in Macrophages Promotes the Early Postentry Steps of HIV-1 Infection through Inhibition of p53.
Journal ArticleJ Virol, 93 (7), 2019, ISSN: 0022-538X.
Abstract | Links:
Host mRNA decay proteins influence HIV-1 replication and viral gene expression in primary monocyte-derived macrophages.
Journal ArticleRetrovirology, 16 (1), pp. 3, 2019.
Abstract | Links:
Interferon-β induced in female genital epithelium by HIV-1 glycoprotein 120 via Toll-like-receptor 2 pathway acts to protect the mucosal barrier.
Journal ArticleCell Mol Immunol, 16 (2), pp. 178-194, 2019, ISSN: 1672-7681.
Abstract | Links:
A new tool for detection of extracellular traps.
Journal ArticleMethods Appl Fluoresc, 6 (3), pp. 037002, 2018, ISSN: 2050-6120.
Abstract | Links:
SAMHD1 Phosphorylation Coordinates the Anti-HIV-1 Response by Diverse Interferons and Tyrosine Kinase Inhibition.
Journal ArticleMBio, 9 (3), 2018.
Abstract | Links:
Astrocytes sustain long-term productive HIV-1 infection without establishment of reactivable viral latency.
Journal ArticleGlia, 66 (7), pp. 1363-1381, 2018, ISSN: 0894-1491.
Abstract | Links:
Contrasting effect of the latency-reversing agents bryostatin-1 and JQ1 on astrocyte-mediated neuroinflammation and brain neutrophil invasion.
Journal ArticleJ Neuroinflammation, 14 (1), pp. 242, 2017.
Abstract | Links:
Frequency of Human CD45+ Target Cells is a Key Determinant of Intravaginal HIV-1 Infection in Humanized Mice.
Journal ArticleSci Rep, 7 (1), pp. 15263, 2017, ISSN: 2045-2322.
Abstract | Links:
Active projects
- Canadian HIV Cure Enterprise 2.0: Targeting the interplay between myeloid cells and C04+ T-cells for HIV cure, Subvention, Instituts de recherche en santé du Canada, Subvention d'équipe : Recherche biomédicale et clinique sur le VIH/sida, from 2019-04-01 to 2024-03-31
- Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
- Centre de recherche en infectiologie, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-06-01 to 2024-11-06
- Chaire du recherche du Canada en immuno-rétrovirologie humaine, Subvention, Secrétariat des Chaires de recherche du Canada, Chaires de recherche du Canada - Fonctionnement, from 2015-01-01 to 2021-12-31
Recently finished projects
- Development of a safe, effective and clinically acceptable VSV-based HIV vaccine, Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2017-04-01 to 2020-03-31
- Journée de la recherche de la Faculté de médecine, Subvention, Institutionnel - BDR, Fonds général de recherche du CRSNG, from 2010-11-24 to 2020-03-31
- Possible outcomes of Leishmania co-infection on HIV-1 immunopathogenesis, latency and reactivation., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2014-07-01 to 2019-06-30